Neuromyelitis optica spectrum disorder diagnostic study of choice

Neuromyelitis optica spectrum disorder Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Neuromyelitis optica spectrum disorder from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Radiation therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Neuromyelitis optica spectrum disorder diagnostic study of choice On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Neuromyelitis optica spectrum disorder diagnostic study of choice All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Neuromyelitis optica spectrum disorder diagnostic study of choice
CDC on Neuromyelitis optica spectrum disorder diagnostic study of choice
Neuromyelitis optica spectrum disorder diagnostic study of choice in the news
Blogs on Neuromyelitis optica spectrum disorder diagnostic study of choice
Directions to Hospitals Treating Neuromyelitis optica spectrum disorder
Risk calculators and risk factors for Neuromyelitis optica spectrum disorder diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes

Overview

• There is no single stand-alone gold-standard investigation for neuromyelitis optica spectrum disorder (NMOSD). Diagnosis requires integration of a compatible core clinical characteristic, serum aquaporin-4 immunoglobulin G (AQP4-IgG) serostatus, magnetic resonance imaging (MRI) findings, and exclusion of a better alternative diagnosis.
• The preferred serologic study is detection of serum AQP4-IgG with a validated live or fixed cell-based assay (CBA). A positive result is highly supportive in the appropriate clinical setting, but the result must not be interpreted independently of the clinical syndrome and exclusion of competing diagnoses.
• MRI of the brain and entire spinal cord is an essential complementary diagnostic study. Dedicated orbital MRI is recommended when optic neuritis is suspected or when optic-nerve lesion length or chiasmal involvement is needed to satisfy diagnostic criteria.
• The currently established diagnostic framework is the 2015 International Panel for Neuromyelitis Optica Diagnosis (IPND) consensus criteria. These criteria remain endorsed by the 2023 Neuromyelitis Optica Study Group (NEMOS) recommendations and the 2026 Middle East and North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) guidelines.
• The 2026 French practice guideline likewise emphasizes serum AQP4-IgG detection and characteristic optic-nerve and spinal-cord MRI findings in the diagnostic assessment.

Diagnostic Study of Choice

Study of choice

• There is no single diagnostic study of choice that confirms or excludes NMOSD in isolation.
• In a patient with a compatible core clinical characteristic, the preferred laboratory investigation is serum AQP4-IgG testing by a validated CBA. Cranial and spinal MRI are mandatory components of the initial diagnostic workup; orbital MRI is added when clinically indicated.
• AQP4-IgG positivity alone is insufficient when the clinical presentation is incompatible with NMOSD or a better alternative diagnosis is present. Conversely, a negative AQP4-IgG result does not exclude NMOSD; patients with negative or unknown serostatus must satisfy the more stringent clinical and MRI requirements shown below.

Role of diagnostic studies

Diagnostic studies used in suspected NMOSD

Study	Recommended use	Diagnostic interpretation
Serum AQP4-IgG by CBA	Obtain in every patient with a core clinical characteristic compatible with NMOSD. Serum is the specimen of choice, and either a validated live or fixed CBA may be used.	This is the key disease-associated serologic study. A positive result supports NMOSD with AQP4-IgG when at least one core clinical characteristic is present and alternative diagnoses have been excluded. A negative result does not independently exclude NMOSD.
MRI of the brain and entire spinal cord	Perform as part of the initial diagnostic workup. Use contrast-enhanced imaging at onset when not contraindicated to characterize active lesions and help exclude inflammatory, vascular, compressive, infectious, and neoplastic mimics.	MRI establishes lesion location and extent, supplies required supportive findings in AQP4-IgG-negative or unknown cases, and assists exclusion of alternative diagnoses. No single MRI finding is independently confirmatory.
Dedicated orbital MRI	Obtain when optic neuritis is suspected, particularly when routine brain MRI does not adequately define the optic nerves or chiasm.	Demonstration of a longitudinally extensive optic-nerve lesion or chiasmal involvement may satisfy an additional MRI requirement in AQP4-IgG-negative or unknown disease.
Serum myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) by CBA	Obtain in clinically appropriate AQP4-IgG-negative patients, particularly before assigning a diagnosis of double-seronegative NMOSD.	A patient who fulfills the international criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) should be classified as having MOGAD, not NMOSD.
Cerebrospinal fluid (CSF) analysis	Lumbar puncture is strongly recommended when needed to distinguish NMOSD from infectious, inflammatory, malignant, and other competing diagnoses.	CSF analysis is supportive and is not formally required by the IPND criteria. CSF AQP4-IgG positivity without serum positivity is not sufficient for classification as AQP4-IgG-positive NMOSD and requires expert review and confirmatory retesting.
Adjunctive ophthalmic and neurophysiologic studies	Optical coherence tomography (OCT) and visual evoked potentials (VEPs) may document optic-pathway injury when clinically appropriate.	These studies may support evaluation of optic neuritis or a differential diagnosis, but neither is a stand-alone diagnostic test nor a required IPND criterion for NMOSD.

AQP4-IgG test interpretation

• AQP4-IgG and MOG-IgG should be measured with CBAs that use conformationally intact, full-length human target proteins. Enzyme-linked immunosorbent assay (ELISA), immunoblot, and peptide-based methods are not preferred for routine diagnosis because they are less sensitive and/or specific than CBA.
• Whenever feasible, serum should be collected before immunotherapy or therapeutic plasma exchange because these exposures may reduce antibody concentrations and cause an equivocal or false-negative result. The sampling time and treatment status should be documented for interpretation.
• A low-positive or clinically discordant positive result should be confirmed with a methodologically different CBA or, if that is unavailable, in a second serum sample. Confirmation is particularly important when red flags for an alternative diagnosis are present.
• If the initial result is negative but clinical suspicion remains high, repeat serum testing should be considered, preferably during an acute attack or a treatment-free interval and, when available, with a standardized live CBA.
• The laboratory report and clinical record should identify the specimen, assay method, result, titer and cutoff when available, and the patient's attack and treatment status at the time of sampling.

Sequence of diagnostic studies

1. Identify whether the patient has one of the six NMOSD core clinical characteristics.
2. Obtain serum AQP4-IgG using a validated CBA, ideally before immunotherapy when feasible.
3. Obtain MRI of the brain and the entire spinal cord; add dedicated orbital MRI when optic neuritis is suspected or when optic-nerve criteria must be assessed.
4. Apply the 2015 IPND criteria according to AQP4-IgG serostatus and exclude a better alternative diagnosis.
5. If AQP4-IgG is negative or unknown, verify the stricter clinical and MRI requirements, obtain serum MOG-IgG testing when clinically appropriate, and consider repeat AQP4-IgG testing if suspicion remains high.
6. Use CSF analysis and selected adjunctive studies only to support the diagnosis or evaluate competing diagnoses; no adjunctive result replaces the required clinical, serologic, and MRI assessment.

International Panel for Neuromyelitis Optica Diagnosis Criteria

Diagnostic requirements according to AQP4-IgG serostatus

2015 IPND diagnostic criteria for NMOSD

Serologic category	Required elements
NMOSD with AQP4-IgG	At least one core clinical characteristic; and Positive serum AQP4-IgG detected with the best available method, with CBA strongly recommended; and Exclusion of alternative diagnoses.
NMOSD without AQP4-IgG or with unknown AQP4-IgG status	At least two core clinical characteristics resulting from one or more attacks and meeting all of the following: At least one characteristic is optic neuritis, acute myelitis with longitudinally extensive transverse myelitis (LETM), or area postrema syndrome; Dissemination in space is demonstrated by two or more different core clinical characteristics; and The applicable additional MRI requirements are fulfilled; and Negative AQP4-IgG testing with the best available method, or testing is unavailable; and Exclusion of alternative diagnoses.

Adapted from the 2015 International Panel for Neuromyelitis Optica Diagnosis consensus criteria; retained and endorsed by the 2023 NEMOS and 2026 MENACTRIMS recommendations.

Core clinical characteristics

Core clinical characteristics of NMOSD

No.	Core characteristic	Definition or required association
1	Acute optic neuritis	An acute inflammatory optic neuropathy compatible with optic neuritis.
2	Acute myelitis	An acute inflammatory spinal-cord syndrome compatible with myelitis.
3	Area postrema syndrome (APS)	Otherwise unexplained hiccups and/or nausea and vomiting, generally lasting at least 48 hours or accompanied by MRI evidence of a dorsal medullary/area postrema lesion.
4	Acute brainstem syndrome other than APS	An acute syndrome localizing to the brainstem.
5	Acute diencephalic syndrome	Symptomatic narcolepsy or another acute diencephalic syndrome accompanied by an NMOSD-typical MRI lesion, such as a periependymal third-ventricular or hypothalamic/thalamic lesion.
6	Acute cerebral syndrome	An acute cerebral syndrome accompanied by an NMOSD-typical MRI lesion, such as an extensive periependymal lateral-ventricular lesion; a long, diffuse, heterogeneous or edematous corpus-callosum lesion; a long corticospinal-tract lesion; or a large confluent subcortical or deep white-matter lesion.

Adapted from the 2015 IPND criteria and the 2023 NEMOS recommendations.

Additional MRI requirements when AQP4-IgG is negative or unknown

Additional MRI requirements in AQP4-IgG-negative or unknown NMOSD

Clinical presentation	Required MRI finding
Acute optic neuritis	Either (1) brain MRI showing normal findings or only nonspecific white-matter lesions, or (2) optic-nerve MRI showing a T2-weighted hyperintense or T1-weighted gadolinium-enhancing lesion extending over at least one-half of the optic-nerve length or involving the optic chiasm.
Acute myelitis	An associated intramedullary MRI lesion extending over at least three contiguous vertebral segments (LETM), or focal spinal-cord atrophy extending over at least three contiguous vertebral segments in a patient with a compatible history of acute myelitis.
Area postrema syndrome	An associated lesion in the dorsal medulla oblongata/area postrema.
Acute brainstem syndrome	An associated periependymal brainstem lesion.

Adapted from the 2015 IPND criteria and the 2023 NEMOS recommendations.

Diagnostic interpretation

• AQP4-IgG-negative and unknown serostatus are not interchangeable. Unknown status should be documented as such, and serum AQP4-IgG testing should be performed at the earliest opportunity.
• MRI abnormalities may support NMOSD but are not pathognomonic. Lesion location, morphology, evolution, and the complete clinical-serologic context must be considered.
• Patients who are AQP4-IgG negative and fulfill the international MOGAD criteria should be diagnosed with MOGAD rather than NMOSD.
• No validated sensitivity-and-specificity comparison between AQP4-IgG testing, MRI, CSF analysis, OCT, and VEPs should be used to choose one investigation over the others because these studies evaluate different components of the diagnostic framework.